Encorafenib, binimetinib and cetuximab combined therapy for patients with mutant metastatic colorectal cancer.

Approximately 10-15% of colorectal cancers (CRCs) harbor an activating mutation, leading to tumor growth promotion by activation of the mitogen-activated protein kinases pathway. mutations are prognostic for treatment failure after first-line systemic therapy in the metastatic setting. In contrast to the efficacy of combined BRAF and MEK inhibition in melanoma, mutant CRC is intrinsically unresponsive due to upregulation of HER/EGFR.